• Human LRRC4 protein (Recombinant) (C-His) (STJP001209)

Human LRRC4 protein (Recombinant) (C-His) (STJP001209)

SKU:
STJP001209

Current Stock:
Host: HEK293 cells
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Recombinant-Human LRRC4-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications.
Formulation: Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation.
Gene Symbol: LRRC4
Gene ID: 64101
Uniprot ID: LRRC4_HUMAN
Immunogen Region: Ala39-Lys527
Immunogen: Recombinant Human LRRC4 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ala39-Lys527) of human LRRC4 (Accession #NP_071426.1.) fused with a 6×His tag at the C-terminus.
Tissue Specificity Specifically expressed in brain.
Post Translational Modifications N-glycosylated.
Function Synaptic adhesion protein. Regulates the formation of exitatory synapses through the recruitment of pre-and-postsynaptic proteins. Organize the lamina/pathway-specific differentiation of dendrites. Plays an important role for auditory synaptic responses. Involved in the suppression of glioma.
Protein Name Leucine-Rich Repeat-Containing Protein 4
Brain Tumor-Associated Protein Bag
Nasopharyngeal Carcinoma-Associated Gene 14 Protein
Netrin-G2 Ligand
Ngl-2
Cellular Localisation Membrane
Single-Pass Type I Membrane Protein
Postsynaptic Cell Membrane
Lrrc4 And Dlg4 Are Interdependent For Synaptic Localization
Alternative Protein Names Leucine-Rich Repeat-Containing Protein 4 protein
Brain Tumor-Associated Protein Bag protein
Nasopharyngeal Carcinoma-Associated Gene 14 Protein protein
Netrin-G2 Ligand protein
Ngl-2 protein
LRRC4 protein
BAG protein
NAG14 protein
UNQ554 protein
PRO1111 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance